Exposure Response Analysis of Safety of Elotuzumab in Patients with Multiple Myeloma

被引：0
|
作者：
Passey, Chaitali [1 ]
Gibiansky, Leonid [2 ]
Sheng, Jennifer [1 ]
Bello, Akintunde [1 ]
Roy, Amit [1 ]
Gupta, Manish [1 ]
机构：
[1] Bristol Myers Squibb, Clin Pharmacol & Pharmacometr, Princeton, NJ USA
[2] QuantPharm LLC, North Potomac, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
T-81
引用
收藏
页码：S85 / S85
页数：1
相关论文
共 50 条
  • [21] Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients
    Neyer, Lauri
    Ding, Han
    Chen, Doreen
    Sheridan, James P.
    Rice, Audie
    Balasa, Balaji
    Keller, Steve
    Fang, Yuni
    Albano, Angie
    Tran, Ninian
    Zhao, Vivian
    Afar, Daniel E. H.
    BLOOD, 2010, 116 (21) : 1658 - 1658
  • [22] Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma Comment
    Touzeau, Cyrille
    LANCET HAEMATOLOGY, 2022, 9 (06): : E386 - E387
  • [23] Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study
    Kaneko, Fumiya
    Suzuka, Hiroshi
    Yoshino, Tomoaki
    Hinosugi, Ryosuke
    INTERNAL MEDICINE, 2024, 63 (22) : 3039 - 3048
  • [24] Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
    Jagannath, Sundar
    Laubach, Jacob
    Wong, Ellice
    Stockerl-Goldstein, Keith
    Rosenbaum, Cara
    Dhodapkar, Madhav
    Jou, Ying-Ming
    Lynch, Mark
    Robbins, Michael
    Shelat, Suresh
    Anderson, Kenneth C.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) : 495 - 503
  • [25] Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Dimopoulos, Meletios
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Oakervee, Heather
    Orlowski, Robert Z.
    Taniwaki, Masafumi
    Roellig, Christoph
    Einsele, Hermann
    Wu, Ka Lung
    Singhal, Anil
    San-Miguel, Jesus
    Matsumoto, Morio
    Katz, Jessica
    Bleickardt, Eric
    Poulart, Valerie
    Anderson, Kenneth C.
    Richardson, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (07): : 621 - 631
  • [26] Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Lamb, Yvette N.
    DRUGS, 2018, 78 (14) : 1481 - 1488
  • [27] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1811 - 1822
  • [28] Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Yvette N. Lamb
    Drugs, 2018, 78 : 1481 - 1488
  • [29] Elotuzumab reduces risk of multiple myeloma progression
    Nature Reviews Clinical Oncology, 2015, 12 (9) : 502 - 502
  • [30] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
12345